RESUMO
BACKGROUND/OBJECTIVE: The aim of this study was to explore the associations between nailfold videocapillaroscopy (NVC) and pulmonary function tests (PFTs) in systemic sclerosis (SSc) patients. METHODS: This was a longitudinal study with follow-up of unselected Brazilian SSc patients. Baseline clinical examination, serological workup, high-resolution chest tomography, and NVC were performed. Pulmonary function test was performed at baseline and after 24 months. Pulmonary function test worsening over time was defined as either a ΔFVC decline ≥10% or a ΔFVC decline ≥5% and <9%, combined with a ΔDLCO decline ≥15%, at 24 months. The NVC parameters were quantitatively (capillary density number, dimension, morphology, and hemorrhages) and qualitatively (NVC pattern) evaluated according to the consented standardized definitions of the EULAR Study Group on Microcirculation in Rheumatic Diseases. RESULTS: Seventy-nine patients were included. Fifty-nine were rated to have a scleroderma pattern (6 "early"/16 "active"/37 "late"). The mean FVC and DLCO were 76.8% and 67.2% at baseline and 73.8% and 64.3% at 24 months, respectively. After multivariate analysis, we found that a reduced baseline FVC was associated with reduced capillary density (odds ratio [OR], 11; 95% confidence interval [CI], 1.5-90.7; p = 0.03) and a reduced baseline DLCO associated with the late scleroderma pattern (OR, 6.75; 95% CI, 1.09-42; p = 0.03). No association between worsening of PFT over time and NVC was found. CONCLUSIONS: The association between NVC and PFTs might corroborate the link between microangiopathy and interstitial lung disease in patients with SSc. This finding might strengthen the idea of incorporating NVC as a tool to predict progressive interstitial lung disease in these patients in the future.
Assuntos
Doenças Pulmonares Intersticiais , Escleroderma Sistêmico , Capilares , Seguimentos , Humanos , Estudos Longitudinais , Angioscopia Microscópica , Unhas , Testes de Função Respiratória , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/diagnósticoRESUMO
BACKGROUND: Systemic sclerosis (SSc) is a rare disease, and the presence of pulmonary hypertension can be a determining factor in prognosis. The aim of this study was to evaluate the diagnosis, profile, and prognosis of systemic sclerosis pulmonary hypertension (SSc-PH) diagnosed by systematic screening in a Brazilian population. METHODS: A cohort of SSc patients underwent systematic screening for SSc-PH. Patients were referred for right heart catheterization (RHC) according to transthoracic echocardiogram or a combination of diagnostic tools. The clinical, immunological, and hemodynamic features and prognosis after 3 years were evaluated. RESULTS: Twenty patients underwent RHC. SSc pulmonary arterial hypertension (SSc-PAH) was the most common group of SSc-PH. These patients had long disease duration, high urate levels and highly elevated mean pulmonary arterial pressure (mPAP) and peripheral vascular resistance (PVR) on hemodynamics. Patients with mPAP > 20- < 25 mmHg had hemodynamic features of intermediate disease. Patients with SSc-PH associated to interstitial lung disease (SSc-ILD-PH) had signs of vasculopathy on hemodynamics. In patients with no-SSc-PH, the survival at 1, 2, and 3 years was 96%, 92% and 92%, respectively and in patients with SSc-PH it was 86.7%, 60% and 53.3%, respectively. CONCLUSIONS: Patients identified with SSc-PAH and SSc-ILD-PH in our screening had severe clinical and hemodynamic features. Mortality remains high in SSc-PH but was more related to Bo-PAH and SSc-ILD-PH, while in SSc-PAH, the prognosis was better. TRIAL REGISTRATION: Current Controlled Trials ISRCTN 72968188, July 8th, 2021. Retrospectively registered.
Assuntos
Hemodinâmica , Hipertensão Pulmonar/diagnóstico , Doenças Pulmonares Intersticiais/fisiopatologia , Hipertensão Arterial Pulmonar/diagnóstico , Escleroderma Sistêmico/fisiopatologia , Adulto , Brasil , Cateterismo Cardíaco , Feminino , Seguimentos , Humanos , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/fisiopatologia , Doenças Pulmonares Intersticiais/complicações , Masculino , Pessoa de Meia-Idade , Prognóstico , Hipertensão Arterial Pulmonar/complicações , Hipertensão Arterial Pulmonar/fisiopatologia , Estudos Retrospectivos , Escleroderma Sistêmico/complicações , Resistência VascularRESUMO
The aim of the present study was to explore whether polymyositis may be considered as an isolated, organ-specific disease or more suitably as a secondary or associated entity. A retrospective re-evaluation of all the muscle biopsies performed at the Hospital Clínic of Barcelona showing histopathological pattern of polymyositis from January 1997 to May 2012 was carried out. The medical records of the patients with the aforementioned pathological pattern were also reviewed. From 1.290 muscle biopsies performed during the period evaluated, 36 with polymyositis pattern were identified. At the time of muscle biopsy, polymyositis pattern was secondary or associated with other disease in 26 patients and was classified as isolated in the remaining ten patients. After pathological re-evaluation and long-term clinical follow-up, only one patient remained with this diagnosis. Overall, the main final diagnosis related to the initial polymyositis pattern was inflammatory myopathy associated with connective tissue disease. Several other associated conditions were also identified. Isolated polymyositis is highly uncommon. Ruling out potential associated or confusing entities, like inclusion body myositis, overlap syndromes, infections, and cancer, is mandatory.
Assuntos
Doenças Autoimunes/complicações , Doenças do Tecido Conjuntivo/complicações , Músculo Esquelético/patologia , Neoplasias/complicações , Polimiosite/etiologia , Viroses/complicações , Adulto , Idoso , Doenças Autoimunes/diagnóstico , Estudos de Coortes , Doenças do Tecido Conjuntivo/diagnóstico , Bases de Dados Factuais , Diagnóstico Diferencial , Progressão da Doença , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Miosite/diagnóstico , Miosite/etiologia , Miosite de Corpos de Inclusão/diagnóstico , Neoplasias/diagnóstico , Polimiosite/diagnóstico , Estudos Retrospectivos , Viroses/diagnóstico , Adulto JovemRESUMO
UNLABELLED: Diagnosis of Sjögren's syndrome (SS) is complex and the usefulness of labial minor salivary glands biopsy in this process remains controversial. OBJECTIVE: to evaluate the clinical and laboratorial profile and histological features on labial minor salivary glands from patients under investigation of SS. STUDY DESIGN: clinical charts from 38 patients under suspicion of SS and submitted to labial minor salivary glands biopsies were reviewed. Clinical and laboratorial data were retrieved from the clinical files and the HE-stained histological slides were reviewed under light microscopy. RESULTS: mean age of the patients was 56.5 years and 97% were females; histological analysis showed that 42% of the cases showed ductal dilatation, lymphocytic foci were found in 52.6% and, from this group, 80% of the cases presented a foci/lobules ratio above 0.8. Acinar/ductal ratio was considered diminished in 39.5% of the samples. Thirty six (95%) and 32 (84%) patients, respectively, complained about xerostomia and xerophthalmia. A study of the time interval of the symptoms that led to SS investigation showed a mean of 116 months. Moreover, sixty-six percent of the patients had already been submitted to immunosuppressive therapy prior to the labial minor salivary gland biopsy. Age of the patients, scintigraphic alterations on salivary function, antinuclear factor (ANF), anti-Ro and anti-La did not show statistical significant association with the histological features. Lobules/foci ratio above 0.8 was the only histological parameter statistically associated with Sjögren's syndrome diagnosis (p<0.0001). CONCLUSIONS: in the studied sample, lymphocytic foci on salivary glands were the only histological parameter associated to the diagnosis of SS. Early indication of labial minor salivary gland biopsy to patients under investigation of SS could limit the effects of immunosuppressive therapy on the histological features associated with the evolution of salivary gland involvement in SS.
Assuntos
Glândulas Salivares Menores/patologia , Síndrome de Sjogren/patologia , Adulto , Idoso , Biópsia , Técnicas de Laboratório Clínico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
BACKGROUND: This research is recommended by the Myopathy Committee of the Brazilian Society of Rheumatology for the investigation and diagnosis of systemic autoimmune myopathies. BODY: A systematic literature review was performed in the Embase, Medline (PubMed) and Cochrane databases, including studies published until October 2018. PRISMA was used for the review, and the articles were evaluated, based on the Oxford levels of evidence. Ten recommendations were developed addressing different aspects of systemic autoimmune myopathy investigation and diagnosis. CONCLUSIONS: The European League Against Rheumatism/ American College of Rheumatology (EULAR/ACR) classification stands out for the diagnosis of systemic autoimmune myopathies. Muscular biopsy is essential, aided by muscular magnetic resonance images and electroneuromyography in complementary research. Analysis of the factors related to prognosis with the evaluation of extramuscular manifestations, and comorbidities and intense investigation regarding differential diagnoses are mandatory.
Assuntos
Doenças Autoimunes/diagnóstico , Doenças Musculares/diagnóstico , Autoanticorpos/sangue , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/patologia , Biópsia , Brasil , Creatina Quinase/sangue , Dermatomiosite/diagnóstico , Eletromiografia/métodos , Humanos , Imageamento por Ressonância Magnética , Metanálise como Assunto , Debilidade Muscular/complicações , Músculo Esquelético/patologia , Doenças Musculares/tratamento farmacológico , Doenças Musculares/imunologia , Doenças Musculares/patologia , Miosite/diagnóstico , Miosite/imunologia , Miosite/patologia , Neoplasias/diagnóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Reumatologia , Sensibilidade e Especificidade , Sociedades MédicasRESUMO
BACKGROUND: Recommendations of the Myopathy Committee of the Brazilian Society of Rheumatology for the management and therapy of systemic autoimmune myopathies (SAM). MAIN BODY: The review of the literature was done in the search for the Medline (PubMed), Embase and Cochrane databases including studies published until June 2018. The Prisma was used for the systematic review and the articles were evaluated according to the levels of Oxford evidence. Ten recommendations were developed addressing the management and therapy of systemic autoimmune myopathies. CONCLUSIONS: Robust data to guide the therapeutic process are scarce. Although not proven effective in controlled clinical trials, glucocorticoid represents first-line drugs in the treatment of SAM. Intravenous immunoglobulin is considered in induction for refractory cases of SAM or when immunosuppressive drugs are contra-indicated. Consideration should be given to the early introduction of immunosuppressive drugs. There is no specific period determined for the suspension of glucocorticoid and immunosuppressive drugs when individually evaluating patients with SAM. A key component for treatment in an early rehabilitation program is the inclusion of strength-building and aerobic exercises, in addition to a rigorous evaluation of these activities for remission of disease and the education of the patient and his/her caregivers.
Assuntos
Doenças Autoimunes/tratamento farmacológico , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Doenças Musculares/tratamento farmacológico , Adulto , Doenças Autoimunes/reabilitação , Biomarcadores/sangue , Brasil , Dermatomiosite/terapia , Exercício Físico , Terapia por Exercício , Glucocorticoides/efeitos adversos , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Imunossupressores/efeitos adversos , Metilprednisolona/administração & dosagem , Metilprednisolona/efeitos adversos , Doenças Musculares/reabilitação , Educação de Pacientes como Assunto , Polimiosite/terapia , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Reumatologia , Rituximab/uso terapêutico , Sociedades MédicasRESUMO
OBJECTIVE: The aim of this work was to produce a consensus-based report for capillaroscopy in rheumatology to be used in daily clinical practice. METHODS: A written Delphi questionnaire regarding capillaroscopy report was developed from a literature review and expert consensus. The Delphi questionnaire was sent to an international panel including 25 rheumatologists experts in capillaroscopy, asking them to rate their level of agreement or disagreement with each statement. The exercise consisted of three online rounds and a face-to-face (live meeting) that took place in the PANLAR 2018 congress held in Buenos Aires, Argentina. RESULTS: The participants to the first, second, third, and face-to-face round were 22, 21, 21, and 16 rheumatologists, respectively. Fifty-five items were discussed in the first round, 58 in the second, 22 in the third, and 9 in the face-to-face meeting. At the end of the exercise, 46 recommendations for the capillaroscopy report in rheumatology reached a consensus. CONCLUSION: This is the first consensus-based report in capillaroscopy. It will be useful in daily clinical practice and to address the effort of the standardization in the technique. KEY POINTS: ⢠The current lack of consensus for the capillaroscopy report makes difficult the interpretation of findings as well as follow-up of rheumatic diseases. ⢠This study produced the first international consensus for the format and content of the naifold capillaroscopy report in rheumatology. ⢠The report is an integral part of the capillaroscopy examination and its use in a homogeneous form can help in the correct interpretation of findings in daily practice.
Assuntos
Angioscopia Microscópica/métodos , Unhas/irrigação sanguínea , Doenças Reumáticas/diagnóstico por imagem , Reumatologia , Consenso , Humanos , Unhas/diagnóstico por imagemRESUMO
BACKGROUND: In scleroderma, excessive collagen production can alter tracheal geometry, and computed tomography (CT) volumetry of this structure may aid in detecting possible abnormalities. The objectives of this study were to quantify the morphological abnormalities in the tracheas of ââpatients with scleroderma and to correlate these findings with data on clinical and pulmonary function. METHODS: This was a cross-sectional study in which 28 adults with scleroderma and 27 controls matched by age, gender and body mass index underwent chest CT with posterior segmentation and skeletonization of the images. In addition, all participants underwent pulmonary function tests and clinical evaluation, including the modified Rodnan skin score (mRSS). RESULTS: Most patients (71.4%) had interstitial lung disease on CT. Compared to controls, patients with scleroderma showed higher values ââin the parameters measured by CT trachea volumetry, including area, eccentricity, major diameter, minor diameter, and tortuosity. The tracheal area and equivalent diameter were negatively correlated with the ratio between forced expiratory flow and forced inspiratory flow at 50% of forced vital capacity (FEF50%/FIF50%) (r = -0.44, p = 0.03 and r = -0.46, p = 0.02, respectively). The tracheal tortuosity was negatively correlated with peak expiratory flow (r = -0.51, p = 0.008). The mRSS showed a positive correlation with eccentricity (r = 0.62, p < 0.001) and tracheal tortuosity (r = 0.51, p = 0.007), while the presence of anti-topoisomerase I antibody (ATA) showed a positive correlation with tracheal tortuosity (r = 0.45, p = 0.03). CONCLUSIONS: In a sample composed predominantly of scleroderma patients with associated interstitial lung disease, there were abnormalities in tracheal geometry, including greater eccentricity, diameter and tortuosity. In these patients, abnormalities in the geometry of the trachea were associated with functional markers of obstruction. In addition, tracheal tortuosity was correlated with cutaneous involvement and the presence of ATA.
Assuntos
Escleroderma Sistêmico/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Traqueia/diagnóstico por imagem , Estudos Transversais , Feminino , Humanos , Doenças Pulmonares Intersticiais/complicações , Doenças Pulmonares Intersticiais/diagnóstico por imagem , Doenças Pulmonares Intersticiais/patologia , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/patologia , Traqueia/patologiaRESUMO
OBJECTIVE: To investigate the effect of rituximab on microcirculation in long-term SSc. RESULTS: Four patients with diffuse SSc over 3 years of disease received rituximab cycles of two 1-g infusions every 6 months for 2 years. Videocapillaroscopy was performed at baseline, 12 months, and 24 months and semi-quantitative scoring of videocapillaroscopy abnormalities was performed and the microangiopathy evolution score (MES: range 0-9) was calculated. The mean disease duration was 5 years (range 3-15). On videocapillaroscopy, giant capillaries and hemorrhages remained stable from baseline to 24 months. Capillary loss, abnormally-shaped capillaries, and MES stabilized at 12 months and increased by 24.5% and 28% at 24 months. Rituximab improves microcirculation in long-term SSc. Stabilization and reduced progression of microcirculation abnormalities were achieved at 12 and 24 months, respectively.
Assuntos
Microcirculação , Rituximab/uso terapêutico , Escleroderma Sistêmico/sangue , Escleroderma Sistêmico/tratamento farmacológico , Adulto , Feminino , Humanos , Masculino , Microcirculação/efeitos dos fármacos , Angioscopia Microscópica , Pessoa de Meia-Idade , Testes de Função Respiratória , Rituximab/farmacologia , Escleroderma Sistêmico/fisiopatologia , Fatores de TempoRESUMO
The term autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) or Shoenfeld's syndrome refers to a wide group of immune-mediated diseases triggered by external agents. Several substances, such as vaccine adjuvants, squalene and silicone implants, are implied in the pathogenesis of ASIA syndrome. Treatment and prognosis of this complex condition are not completely known due to lack of good quality evidence. After a brief introductory literature review on ASIA, we report here two cases of patients that developed rapidly progressive systemic sclerosis clinical features after multiple intramuscular local injections of a substance recommended by a non-medical professional called ADE. ADE is an oily vitamin complex for veterinary use, and it was used in these cases for cosmetic muscular definition and enhancement purpose. To our knowledge, this is the first paper to describe the relation between injections of ADE and the development of ASIA with severe systemic sclerosis phenotype. Further investigation is needed to better understand the pathophysiology and to provide the basis for the treatment of this condition.
Assuntos
Adjuvantes Farmacêuticos/efeitos adversos , Esclerodermia Difusa/induzido quimicamente , Adjuvantes Farmacêuticos/administração & dosagem , Adulto , Humanos , Injeções Intramusculares , Masculino , Rituximab/uso terapêutico , Esclerodermia Difusa/tratamento farmacológico , Esclerodermia Difusa/patologia , Síndrome , Vitamina A/administração & dosagem , Vitamina D/administração & dosagem , Vitamina E/administração & dosagem , Vitaminas/administração & dosagemRESUMO
Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. OBJECTIVE: This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. PATIENTS AND METHODS: We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. RESULTS: Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. DISCUSSION: Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment.
Assuntos
Fatores Imunológicos/uso terapêutico , Rituximab/uso terapêutico , Escleroderma Sistêmico/tratamento farmacológico , Linfócitos B , Humanos , Pulmão , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Dry eye disease (DED) is a multifactorial disease of the tears and ocular surface that causes tear film instability with potential damage to the ocular surface. The prevalence of dry eye in the world population ranges from 6 to 34 %. It is more common in those aged over 50, and affects mainly women. Since the introduction of the Schirmer's test in 1903, other tests have been developed to evaluate dry eye, such as biomicroscopy, the tear film breakup time (BUT), vital dyes (lissamine green and rose bengal), fluorescein, leaf fern test, corneal sensitivity test, conjunctiva impression cytology, optical coherence tomography (OCT), and tear osmolarity measurement. Although there is no gold standard, it is advisable to combine at least two tests. Strategies for treating DED have recently been modified and include patient education, tear substitute, corticosteroids, secretagogues, fatty acids, immunomodulators, occlusion of lacrimal puncta surgery and, tarsorrhaphy. Biological therapy and new topical immunomodulators such as tacrolimus, tofacitinib and IL-1 receptor inhibitor are being tested. In this review, the evaluation tests for dry eye are compared and the main studies on treatment are presented, with emphasis on studies in patients with Sjögren's syndrome. The authors propose an approach for the management of dry eye.
Assuntos
Terapia Biológica , Síndromes do Olho Seco/terapia , Síndrome de Sjogren/terapia , Fatores Etários , Animais , Síndromes do Olho Seco/diagnóstico , Feminino , Humanos , Fatores Imunológicos/uso terapêutico , Masculino , Procedimentos Cirúrgicos Oftalmológicos , Fatores Sexuais , Síndrome de Sjogren/diagnóstico , Tomografia de Coerência ÓpticaRESUMO
The recommendations proposed by the Sjögren's Syndrome Committee of the Brazilian Society of Rheumatology for the treatment of Sjögren's syndrome were based on a systematic review of literature in Medline (PubMed) and the Cochrane databases until October 2014 and on expert opinion in the absence of studies on the subject. 131 items classified according to Oxford & Grade were included. These recommendations were developed in order to guide the appropriate management and facilitate the access to treatment for those patients with an appropriate indication, considering the Brazilian socioeconomic context and pharmacological agents available in this country.
Assuntos
Síndrome de Sjogren/terapia , Brasil , Árvores de Decisões , HumanosRESUMO
Abstract Background: This research is recommended by the Myopathy Committee of the Brazilian Society of Rheumatology for the investigation and diagnosis of systemic autoimmune myopathies. Body: A systematic literature review was performed in the Embase, Medline (PubMed) and Cochrane databases, including studies published until October 2018. PRISMA was used for the review, and the articles were evaluated, based on the Oxford levels of evidence. Ten recommendations were developed addressing different aspects of systemic autoimmune myopathy investigation and diagnosis. Conclusions: The European League Against Rheumatism/ American College of Rheumatology (EULAR/ACR) classification stands out for the diagnosis of systemic autoimmune myopathies. Muscular biopsy is essential, aided by muscular magnetic resonance images and electroneuromyography in complementary research. Analysis of the factors related to prognosis with the evaluation of extramuscular manifestations, and comorbidities and intense investigation regarding differential diagnoses are mandatory.
RESUMO
Abstract Background: Recommendations of the Myopathy Committee of the Brazilian Society of Rheumatology for the management and therapy of systemic autoimmune myopathies (SAM). Main body: The review of the literature was done in the search for the Medline (PubMed), Embase and Cochrane databases including studies published until June 2018. The Prisma was used for the systematic review and the articles were evaluated according to the levels of Oxford evidence. Ten recommendations were developed addressing the management and therapy of systemic autoimmune myopathies. Conclusions: Robust data to guide the therapeutic process are scarce. Although not proven effective in controlled clinical trials, glucocorticoid represents first-line drugs in the treatment of SAM. Intravenous immunoglobulin is considered in induction for refractory cases of SAM or when immunosuppressive drugs are contra-indicated. Consideration should be given to the early introduction of immunosuppressive drugs. There is no specific period determined for the suspension of glucocorticoid and immunosuppressive drugs when individually evaluating patients with SAM. A key component for treatment in an early rehabilitation program is the inclusion of strengthbuilding and aerobic exercises, in addition to a rigorous evaluation of these activities for remission of disease and the education of the patient and his/her caregivers.
Assuntos
Adulto , Humanos , Doenças Autoimunes/tratamento farmacológico , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Doenças Musculares/tratamento farmacológico , Reumatologia , Sociedades Médicas , Doenças Autoimunes/reabilitação , Brasil , Metilprednisolona/administração & dosagem , Metilprednisolona/efeitos adversos , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Biomarcadores/sangue , Exercício Físico , Ensaios Clínicos Controlados Aleatórios como Assunto , Educação de Pacientes como Assunto , Imunoglobulinas Intravenosas/uso terapêutico , Polimiosite/terapia , Dermatomiosite/terapia , Terapia por Exercício , Rituximab/uso terapêutico , Glucocorticoides/efeitos adversos , Imunossupressores/efeitos adversos , Doenças Musculares/reabilitaçãoRESUMO
Abstract Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. Objective This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. Patients and methods We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. Results Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. Discussion Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment.
Resumo A esclerose sistêmica (ES) é uma doença autoimune crônica de alta morbimortalidade. Ainda que a ciclofosfamida seja eficaz, para casos graves e refratários há demanda para novos tratamentos. A terapia biológica com depleção de células B com rituximabe (RTX) demonstrou eficácia para tal demanda em estudos abertos. Objetivo Avaliar retrospectivamente todos os pacientes que fizeram uso do RTX para tratamento de ES em nosso centro. Pacientes e métodos Foram avaliados retrospectivamente todos os prontuários de pacientes com ES que fizeram uso de RTX para tratamento da ES de janeiro de 2009 a janeiro de 2015. Dados de acometimento sistêmico, cutâneo, pulmonar e laboratoriais antes e seis meses após a primeira infusão de RTX foram coletados. Resultados Dez pacientes receberam o tratamento no período de estudo e foram incluídos na presente série de casos. Todos os pacientes tinham a forma difusa da doença. Cinco pacientes tinham formas iniciais (tempo de doença menor ou igual a quatro anos) e rapidamente progressiva da doença e cinco receberam o RTX em fases tardias da doença. Houve estabilização do quadro pulmonar em ambos os grupos de pacientes e redução no escore cutâneo nos pacientes com formas iniciais da doença. Discussão Similar ao encontrado em estudos prévios, o RTX foi eficaz no tratamento de formas iniciais e rapidamente progressivas da ES. Verificamos também benefício em pacientes com longa duração da doença.
Assuntos
Humanos , Escleroderma Sistêmico/tratamento farmacológico , Rituximab/uso terapêutico , Fatores Imunológicos/uso terapêutico , Linfócitos B , Estudos Retrospectivos , Resultado do Tratamento , PulmãoRESUMO
A esclerodermia é uma multissistêmica caracterizada por vasculopatia generalizada, autoimunidade e fibrose orgânica. A hipertensão arterial pulmonar (HAP) é a expressão do acometimento vascular na circulação pulmonar. É a principal causa de mortalidade na esclerodermia. Atualmente prevalência da hipertensão arterial na esclerodermia é estimada em 10%. As manifestações clínicas são inespecíficas e procedimentos anuais de triagem devem ser realizados para seu diagnóstico. O ecocardiograma transtorácico fornece diversos sinais indiretos de HAP tais como aumento da velocidade tricúspide e disfunção de ventrículo direito. Atualmente, a triagem da HAP é realizada através de algoritmos compostos onde o ecocardiograma é indicado após outros exames de triagem. O diagnóstico da HAP é confirmado pelo cateterismo do ventrículo direito. O tratamento deve ser realizado com um fármaco dos três grupos de fármacos específicos. Resultados de registros recentes indicaram que preditivos de pior prognóstico são idade avançada, sexo masculino, teste da caminhada < 165m e alta resistência vascular periférica. A sobrevivência foi maior nos pacientes que receberam diagnóstico precoce e tratamento com novos fármacos específicos. A HAP associada à esclerodermia é uma complicação comum e de alta mortalidade. Estudos recentes sugerem que o diagnóstico precoce seguido da instituição de terapia específica podem aumentar a sobrevivência destes pacientes...
Systemic sclerosis is a systemic disease characterized by generalized vasculopathy, autoimmunity and organic fibrosis. Pulmonary artery hypertension (PAH) is the expression of the vascular involvement in the pulmonary circulation. It is the main cause of mortality in systemic sclerosis.At the present the prevalence of PAH on systemic sclerosis is estimated at 10%. The clinical manifestations are nonspecific and annual screening procedures should be performed for its diagnosis. The transthoracic echocardiogram provides several indirect signs of PAH, this include increase on the tricuspid regurgitation velocity and right ventricle disfunction. Currently, the screening of PAH is performed according to composed algorithms were the echocardiogram is indicated after other screening. The diagnosis of PAH is confirmed by the right ventricule catheterization. The treatment should be done with one drug of the three groups of specific drugs. Recent results od registries disclosed that bad prognosis predictors are: old age, male sex, six minute walk test < 165 and high peripheral vascular resistance. The survival was higher in patients that had early diagnosis and treatment with specific drugs. PAP associated to systemic sclerosis is a frequent and severe complication. Recent studies sugest that early diagnosis followed by introduction of specific medication can increase the survival in these patients...
Assuntos
Humanos , Masculino , Feminino , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/epidemiologia , Hipertensão Pulmonar/terapia , Escleroderma SistêmicoRESUMO
O maior conhecimento da fisiopatologia, prognóstico e tratamento das doenças vasculares e hipertensão arterial pulmonar (HAP) nos últimos anos em associação com novos e promissores tratamentos, ter aumentado o número de pacientes para o laboratório de cateterismo cardíaco ou serviços de hemodinâmica. O manejo dos pacientes com HAP, a correta realização das técnicas de cateterismo cardíaco direito, a qual é considerada o padrão ouro para o diagnóstico de HAP, e a correta interpretação dos dados conseguidos são instrumentos uteis para o seguimento clínico. Logo é fortemente aconselhado que estas técnicas por cardiologistas intervencionistas e em laboratórios de cateterismo cardíaco. Este artigo apresenta uma atualização sobre o assunto...
The great understanding of the pathophysiology, prognosis and treatment of vascular diseases and pulmonary artery hypertension (PAH) over the past years, in association with new promising treatments, increased the number of patients arriving at the cardiac catheterization laboratory (cath lab) or hemodynamic services. The management of such special group of patients as PAH, the correct accomplishment of the techniques of right heart catheterization, which remain the gold standard for diagnosing PAH, and accurate interpretation of collected data are useful tools to clinical follow up. Thereby, it is strongly advised that these techniques be acquired by all interventional cardiologists and in every cath lab. This article presents an update of this issue...
Assuntos
Humanos , Masculino , Feminino , Cateterismo Cardíaco , Insuficiência Cardíaca , Hemodinâmica , Hipertensão PulmonarRESUMO
RESUMOAs recomendações propostas pela Comissão de Síndrome de Sjögren da Sociedade Brasileira de Reumatologia para tratamento da síndrome de Sjögren foram baseadas em uma revisão sistemática da literatura nas bases de dados Medline (PubMed) e Cochrane até outubro de 2014 e opinião de especialistas na ausência de artigos sobre o assunto. Foram incluídos 131 artigos classificados de acordo com Oxford & Grade. Essas recomendações foram elaboradas com o objetivo de orientar o manejo adequado e facilitar o acesso aos tratamentos para aqueles pacientes com adequada indicação de recebê-los, considerando o contexto socioeconômico brasileiro e os medicamentos disponíveis no país.
ABSTRACTThe recommendations proposed by the Sjögren's Syndrome Committee of the Brazilian Society of Rheumatology for the treatment of Sjögren's syndrome were based on a systematic review of literature in Medline (PubMed) and the Cochrane databases until October 2014 and on expert opinion in the absence of studies on the subject. 131 articles classified according to Oxford & Grade were included. These recommendations were developed in order to guide the management and facilitate the access to treatment for those patients with an appropriate indication, considering the Brazilian socioeconomic context and pharmacological agents available in this country.